Do All Breast Cancer Survivors Need to See a Cardiologist?Do All Breast Cancer Survivors Need to See a Cardiologist?
Little is known about the contribution of breast cancer treatments to the long-term development of heart failure (HF) and/or cardiomyopathy (CM) in patients. For some treatments (eg, anthracyclines), specific recommendations for cardiac surveillance are based on the total cumulative dose received. For ERBB2 (formerly HER2)-targeted treatments, monitoring largely occurs in the setting of active treatment, with little guidance for subsequent surveillance or risk assessment. The expanding number of breast cancer survivors, with cardiovascular disease as an important competing cause of mortality, brings attention to understanding who is at risk for HF/CM after breast cancer treatments and whether preventive cardiac surveillance is warranted.
Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal WomenHormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women
This cohort study estimates the difference in breast cancer risk associated with different hormonal contraceptive formulations.
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US WomenPathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women
This study evaluates population-based breast cancer risk estimates for those with established pathogenic variants overall and stratified by first-degree family history of breast cancer and other factors.
GLP-1 Drugs and AMD: What We’ve Learned So FarGLP-1 Drugs and AMD: What We’ve Learned So Far
(MedPage Today) — GLP-1 receptor agonists are being linked to a long list of benefits besides weight loss and diabetes, as evidence suggests they can lower the risk of conditions ranging from cancer and addiction to suicidal ideation, stroke… (MedPage Today) — GLP-1 receptor agonists are being linked to a long list of benefits Read More
A breast cancer researcher at Harvard loses 1/3 of her staff amid NIH funding cutsA breast cancer researcher at Harvard loses 1/3 of her staff amid NIH funding cuts
Amid NIH funding delays, clawbacks and uncertainty, a scientist at Harvard who studies breast cancer has lost one third of her lab employees and wonders if she can continue her research experiments.
Tirzepatide’s benefits fade for most: Weight and health markers rebound after withdrawal, study findsTirzepatide’s benefits fade for most: Weight and health markers rebound after withdrawal, study finds
Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide patients. People with obesity who lost weight on tirzepatide often regained at least 25% of that loss within a year of stopping treatment, along with reversals Read More
Opinion: Public health should embrace GLP-1 drugs without abandoning obesity preventionOpinion: Public health should embrace GLP-1 drugs without abandoning obesity prevention
Following the White House’s recent announcement of price reductions and expanded coverage for GLP-1 medications like Wegovy and Zepbound, many patients searching for obesity treatments are about to gain access to highly effective options. The implications for U.S. public health are vast. Read the rest… Following the White House’s recent announcement of price reductions Read More
Women ‘traumatised’ by breast cancer treatment at NHS trustWomen ‘traumatised’ by breast cancer treatment at NHS trust
More than 200 patients suffered harm, including unnecessary mastectomies, the BBC has been told.
Is Chronic Cough Another Side Effect of GLP-1 Drugs?Is Chronic Cough Another Side Effect of GLP-1 Drugs?
(MedPage Today) — GLP-1 receptor agonist use was associated with chronic cough regardless of a previous gastroesophageal reflux disease (GERD) diagnosis, a study of over 2 million people with type 2 diabetes suggested. Adults prescribed a GLP… (MedPage Today) — GLP-1 receptor agonist use was associated with chronic cough regardless of a previous gastroesophageal Read More
Medicare negotiated lower prices for 15 drugs, including 71% off Ozempic and WegovyMedicare negotiated lower prices for 15 drugs, including 71% off Ozempic and Wegovy
Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include Ozempic and also drugs to treat asthma, breast cancer and leukemia. (Image credit: Eric Thayer) Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include Ozempic and also drugs to Read More